• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional therapies and medications are not effective for a lot of people who are depressed. A customized treatment may be the answer.

Cue is an intervention platform that converts sensor data collected from smartphones into personalised micro-interventions for improving mental health. We analysed the best drug to treat anxiety and depression-fit personalized ML models for each subject using Shapley values to discover their predictors of feature and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

Depression is a leading cause of mental illness across the world.1 Yet only half of those affected receive treatment. To improve the outcomes, doctors must be able to identify and treat patients who are most likely to respond to certain treatments.

Personalized depression treatment can help. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will benefit most from certain treatments. They use sensors on mobile phones, a voice assistant with artificial intelligence as well as other digital tools. Two grants worth more than $10 million will be used to determine biological and behavior factors that predict response.

So far, the majority of research on predictors for depression treatment effectiveness has focused on sociodemographic and clinical characteristics. These include demographics like age, gender and education as well as clinical characteristics like symptom severity and comorbidities, as well as biological markers.

While many of these aspects can be predicted from the information available in medical records, very few studies have employed longitudinal data to study the causes of mood among individuals. Few studies also take into consideration the fact that mood can vary significantly between individuals. Therefore, it is crucial to create methods that allow the determination of the individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. This enables the team to create algorithms that can detect various patterns of behavior and emotions that differ between individuals.

The team also developed an algorithm for machine learning to model dynamic predictors for each person's depression treatment History; https://fakenews.Win/, mood. The algorithm blends the individual differences to create an individual "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores that are a psychometrically validated symptoms severity scale. However the correlation was not strong (Pearson's r = 0.08, adjusted BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is one of the world's leading causes of disability1, but it is often underdiagnosed and undertreated2. In addition an absence of effective interventions and stigmatization associated with depressive disorders prevent many from seeking treatment.

To help with personalized treatment, it is crucial to determine the predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which aren't reliable and only reveal a few symptoms associated with depression.

Machine learning can increase the accuracy of the diagnosis and treatment of agitated depression treatment by combining continuous, digital behavioral patterns gathered from sensors on smartphones with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes capture a large number of distinct behaviors and activities, which are difficult to record through interviews and permit continuous and high-resolution measurements.

The study comprised University of California Los Angeles students who had mild to severe depression symptoms who were taking part in the Screening and Treatment for Anxiety and Depression program29 that was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or clinical care based on the degree of their depression. Patients who scored high on the CAT-DI scale of 35 65 were allocated online support with a peer coach, while those with a score of 75 patients were referred to psychotherapy in-person.

Participants were asked a set of questions at the beginning of the study regarding their demographics and psychosocial characteristics. These included sex, age and education, as well as work and financial status; whether they were divorced, partnered or single; the frequency of suicidal thoughts, intentions or attempts; as well as the frequency at the frequency they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale of 0-100. The CAT DI assessment was carried out every two weeks for participants who received online support, and weekly for those who received in-person care.

Predictors of the Reaction to Treatment

Personalized depression treatment is currently a research priority and a lot of studies are aimed at identifying predictors that allow clinicians to identify the most effective medication for each individual. Pharmacogenetics, in particular, uncovers genetic variations that affect how the body's metabolism reacts to drugs. This enables doctors to choose medications that are likely to work best for each patient, reducing the time and effort required in trial-and-error procedures and avoid any adverse effects that could otherwise hinder the progress of the patient.

Another promising approach is to develop predictive models that incorporate the clinical data with neural imaging data. These models can be used to determine which variables are the most predictive of a particular outcome, like whether a medication will help with symptoms or mood. These models can be used to determine the patient's response to treatment that is already in place, allowing doctors to maximize the effectiveness of treatment currently being administered.

A new type of research employs machine learning techniques such as supervised learning and classification algorithms (like regularized logistic regression or tree-based techniques) to blend the effects of several variables and improve the accuracy of predictive. These models have shown to be useful for forecasting treatment outcomes, such as the response to antidepressants. These methods are becoming more popular in psychiatry, and are likely to become the standard of future treatment.

Research into the underlying causes of depression continues, as well as predictive models based on ML. Recent findings suggest that the disorder is linked with neural dysfunctions that affect specific circuits. This suggests that an individualized depression treatment will be built around targeted treatments that target these neural circuits to restore normal functioning.

Internet-based interventions are an effective method to achieve this. They can provide more customized and personalized experience for patients. For example, one study found that a web-based program was more effective than standard care in improving symptoms and providing an improved quality of life for people suffering from MDD. In addition, a controlled randomized study of a personalised approach to treating depression showed sustained improvement and reduced adverse effects in a large proportion of participants.

Predictors of adverse effects

In the treatment of depression a major challenge is predicting and determining the antidepressant that will cause very little or no adverse effects. Many patients take a trial-and-error approach, with various medications prescribed until they find one that is safe and effective. Pharmacogenetics is an exciting new way to take an efficient and targeted method of selecting antidepressant therapies.

There are a variety of predictors that can be used to determine the antidepressant to be prescribed, including gene variations, phenotypes of the patient such as ethnicity or gender and the presence of comorbidities. However finding the most reliable and reliable predictors for a particular treatment centre for depression is likely to require controlled, randomized trials with much larger samples than those normally enrolled in clinical trials. This is because the detection of interactions or moderators may be much more difficult in trials that only take into account a single episode of treatment per person, rather than multiple episodes of treatment over time.

Additionally, the prediction of a patient's reaction to a particular medication will also likely require information on the symptom profile and comorbidities, as well as the patient's personal experience with tolerability and efficacy. At present, only a few easily measurable sociodemographic and clinical variables seem to be reliably associated with the response to MDD factors, including age, gender, race/ethnicity and SES BMI, the presence of alexithymia and the severity of depression symptoms.

The application of pharmacogenetics in treatment for depression is in its early stages, and many challenges remain. First, a clear understanding of the underlying genetic mechanisms is needed as well as an understanding of what is a reliable indicator of treatment response. Ethics such as privacy and the ethical use of genetic information should also be considered. Pharmacogenetics can, in the long run help reduce stigma around mental health treatment and improve treatment outcomes. As with any psychiatric approach it is essential to give careful consideration and implement the plan. The best option is to offer patients an array of effective medications for depression and encourage them to talk openly with their doctors about their experiences and concerns.